KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Long-Term Debt Repayments (2016 - 2017)

Nektar Therapeutics (NKTR) has 8 years of Long-Term Debt Repayments data on record, last reported at $3.0 million in Q4 2017.

  • For Q4 2017, Long-Term Debt Repayments rose 422.32% year-over-year to $3.0 million; the TTM value through Sep 2018 reached $3.0 million, up 8.94%, while the annual FY2017 figure was $5.1 million, 13.69% down from the prior year.
  • Long-Term Debt Repayments reached $3.0 million in Q4 2017 per NKTR's latest filing, up from $790000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $3.0 million in Q4 2017 and bottomed at $569000.0 in Q4 2016.
  • Average Long-Term Debt Repayments over 5 years is $1.1 million, with a median of $876500.0 recorded in 2014.
  • The widest YoY moves for Long-Term Debt Repayments: up 422.32% in 2017, down 64.42% in 2017.
  • A 5-year view of Long-Term Debt Repayments shows it stood at $791000.0 in 2013, then increased by 21.11% to $958000.0 in 2014, then skyrocketed by 44.99% to $1.4 million in 2015, then tumbled by 59.04% to $569000.0 in 2016, then skyrocketed by 422.32% to $3.0 million in 2017.
  • Per Business Quant database, its latest 3 readings for Long-Term Debt Repayments were $3.0 million in Q4 2017, $790000.0 in Q3 2017, and $756000.0 in Q2 2017.